IMPORTANT SAFETY INFORMATION AND INDICATION

Quick Links

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Radiation Exposure: Treatment with LUTATHERA contributes to a patient’s overall long-term cumulative radiation exposure and is associated with an increased risk for cancer. Radiation can be detected in the urine for up to 30 days following LUTATHERA administration. Minimize radiation exposure to patients, medical personnel, and household contacts during and after treatment with LUTATHERA consistent with institutional good radiation safety practices, patient management procedures, Nuclear Regulatory Commission patient release guidance, and instructions to the patient for follow-up radiation protection at home.

INDICATION

LUTATHERA^® (lutetium Lu 177 dotatate) is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults.

About GEP-NETs

Frequency

NETs Are Being Diagnosed With Increasing Frequency

Neuroendocrine tumors (NETs) arise from neuroendocrine cells, which are specialized cells that secrete hormones and other substances and are found throughout the body. These cancers may or may not secrete substances at levels high enough to cause symptoms.^1-3

Although classified as a rare disease, NETs are being diagnosed with increasing frequency.^4,5

The reported incidence of NETs has increased:

	New cases/year as of 2012⁴
	Projected people living with the disease in the United States as of 2014⁴
	Over the last few decades (from 1973 to 2012)⁴

Diagnosis at earlier stages of the disease is thought to be responsible for this increase, even though NETs are still often diagnosed at an advanced or metastatic stage.^7,8

NETs are generally considered as indolent (slowly growing) tumors; however, the prognosis varies widely, according to⁴:

Primary tumor site
Tumor differentiation and grade
Stage

From 1973 through 2012, the annual age-adjusted incidence of NETs has increased compared with that of other malignant neoplasms.⁴

It may be helpful to educate patients with GEP-NETs and progressive disease about available treatment.^7‑9

Classification

Although NETs can arise from a wide variety of organs and tissues, most NETs are gastroenteropancreatic NETs (GEP-NETs), originating in the gastrointestinal tract and pancreas.⁴

GEP-NETs have traditionally been divided into¹⁰:

Foregut tumors: Esophagus, stomach, proximal duodenum, liver, and pancreas
Midgut tumors: Distal duodenum, ileum, jejunum, ascending colon, and proximal two-thirds of transverse colon
Hindgut tumors: Distal one-third of transverse colon, descending colon, sigmoid colon, and rectum

NETs can present with nonspecific symptoms so the diagnosis may be delayed.¹¹

Delay in Diagnosis

Many patients with GEP-NETs are diagnosed with metastatic disease, which may result in increased disease burden and worse survival outcomes.^4,8,11

Diagnosis of NETs is often delayed.^7,11

of patients with GEP-NETs present with regional spread or distant metastases at time of diagnosis^8,a

^aBased on 837 assessable patients from the National Cancer Registry for Gastroenteropancreatic Neuroendocrine Tumors (RGETNE) in Spain. In this cohort, 14% of patients had regional spread and 44% had distant metastasis.⁸

Act at the time of GEP-NET progression.⁸

Mortality

Advanced GEP-NETs May Be Fatal, Even for Patients With Low-Grade Disease⁴

Most patients are diagnosed with locally advanced or metastatic disease due to the slow-growing nature of the tumor, lack of symptoms, or nonspecific symptoms^11,12
GEP-NETs may be fatal in patients with advanced, nonresectable disease^4,7

Survival rates vary depending on the location of the primary tumor.⁴

Next: Disease Progression

References: 1. National Center for Advancing Translational Sciences. Neuroendocrine tumor. https://rarediseases.info.nih.gov/diseases/13445/neuroendocrine-tumor. Accessed April 8, 2021. 2. National Cancer Institute. Neuroendocrine tumor. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/neuroendocrine-tumor. Accessed April 8, 2021. 3. American Society of Clinical Oncology. Neuroendocrine Tumors: Introduction. https://www.cancer.net/cancertypes/neuroendocrine-tumors/introduction. Accessed June 23, 2021. 4. Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335-1342. 5. US Food and Drug Administration. Rare Diseases at FDA. https://www.fda.gov/patients/rare-diseases-fda. Accessed June 23, 2021. 6. Man D, Wu J, Shen Z, Zhu X. Prognosis of patients with neuroendocrine tumor: a SEER database analysis. Cancer Manag Res. 2018;10:5629-5638. 7. Sackstein PE, O’Neil DS, Neuget AI, Chabot J, Fojo T. Epidemiologic trends in neuroendocrine tumors: an examination of incidence rates and survival of specific patient subgroups over the past 20 years. Semin Oncol. 2018;45(4):249-258. 8. Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol. 2010;21(9):1794-1803. 9. Lutathera [prescribing information]. Millburn, NJ: Advanced Accelerator Applications. 10. Campana D, Tomassetti P. Incidence, epidemiology, aetiology and staging, classification, clinical presentation/signs and symptoms, diagnosis, staging procedures/investigation. In: PET/CT in Neuroendocrine Tumors, Clinicians’ Guides to Radionuclide Hybrid Imaging. 1st ed. AG, Switzerland: Springer International; 2016:1-5. 11. Singh S, Granberg D, Wolin E, et al. Patient-reported burden of a neuroendocrine tumor (NET) diagnosis: results from the first global survey of patients with NETs. J Glob Oncol. 2017;3(1):43-53. 12. Vinik AI, Woltering EA, Warner RRP, et al. NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas. 2010;39(6):713-734.

INDICATION

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Radiation Exposure: Treatment with LUTATHERA contributes to a patient’s overall long-term cumulative radiation exposure and is associated with an increased risk for cancer. Radiation can be detected in the urine for up to 30 days following LUTATHERA administration. Minimize radiation exposure to patients, medical personnel, and household contacts during and after treatment with LUTATHERA consistent with institutional good radiation safety practices, patient management procedures, Nuclear Regulatory Commission patient release guidance, and instructions to the patient for follow-up radiation protection at home.
Myelosuppression: In the NETTER-1 clinical trial, myelosuppression occurred more frequently in patients receiving LUTATHERA with long-acting octreotide compared with patients receiving high-dose long-acting octreotide (all grades/grade 3 or 4): anemia (81%/0 vs 54%/1%), thrombocytopenia (53%/1% vs 17%/0), and neutropenia (26%/3% vs 11%/0). In NETTER-1, platelet nadir occurred at a median of 5.1 weeks following the first dose. Of the 59 patients who developed thrombocytopenia, 68% had platelet recovery to baseline or normal levels. The median time to platelet recovery was 2 months. Fifteen of the 19 patients in whom platelet recovery was not documented had post-nadir platelet counts. Among these 15 patients, 5 improved to grade 1, 9 to grade 2, and 1 to grade 3. Monitor blood cell counts. Withhold, reduce dose, or permanently discontinue based on severity of myelosuppression.
Secondary Myelodysplastic Syndrome and Leukemia: In NETTER-1, with a median follow-up time of 76 months in the main study, myelodysplastic syndrome (MDS) was reported in 2.3% of patients receiving LUTATHERA with long-acting octreotide compared with no patients receiving high-dose long-acting octreotide. In ERASMUS, a phase 2 clinical study, 16 patients (2.0%) developed MDS and 4 (0.5%) developed acute leukemia. The median time to onset was 29 months (range, 9-45 months) for MDS and 55 months (range, 32-125 months) for acute leukemia.
Renal Toxicity: In ERASMUS, 8 patients (<1%) developed renal failure 3 to 36 months following LUTATHERA. Two of these patients had underlying renal impairment or risk factors for renal failure (eg, diabetes or hypertension) and required dialysis. Administer the recommended amino acid solution before, during, and after LUTATHERA to decrease reabsorption of lutetium Lu 177 dotatate through the proximal tubules and decrease the radiation dose to the kidneys. Do not decrease the dose of the amino acid solution if the dose of LUTATHERA is reduced. Advise patients to urinate frequently during and after administration of LUTATHERA. Monitor serum creatinine and calculated creatinine clearance. Withhold, reduce dose, or permanently discontinue LUTATHERA based on severity of renal toxicity. Patients with baseline renal impairment may be at greater risk of toxicity; perform more frequent assessments of renal function in patients with mild or moderate impairment. LUTATHERA has not been studied in patients with severe renal impairment (creatinine clearance <30 mL/min).
Hepatotoxicity: In ERASMUS, 2 patients (<1%) were reported to have hepatic tumor hemorrhage, edema, or necrosis, with 1 patient experiencing intrahepatic congestion and cholestasis. Patients with hepatic metastasis may be at increased risk of hepatotoxicity due to radiation exposure. Monitor transaminases, bilirubin, and serum albumin during treatment. Withhold, reduce dose, or permanently discontinue LUTATHERA based on severity of hepatic impairment.
Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, occurred in patients treated with LUTATHERA. Monitor patients closely for signs and symptoms of hypersensitivity reactions, including anaphylaxis, during and after LUTATHERA administration for a minimum of 2 hours in a setting in which cardiopulmonary resuscitation medication and equipment are available. Discontinue the infusion at the first observation of any signs or symptoms consistent with a severe hypersensitivity reaction and initiate appropriate therapy. Premedicate patients with a history of grade 1 or 2 hypersensitivity reactions to LUTATHERA before subsequent doses. Permanently discontinue LUTATHERA in patients who experience grade 3 or 4 hypersensitivity reactions.
Neuroendocrine Hormonal Crisis: Neuroendocrine hormonal crisis, manifesting with flushing, diarrhea, bronchospasm, and hypotension, occurred in <1% of patients in ERASMUS and typically occurred during or within 24 hours following the initial LUTATHERA dose. Two (<1%) patients were reported to have hypercalcemia. Monitor patients for flushing, diarrhea, hypotension, bronchoconstriction, or other signs and symptoms of tumor-related hormonal release. Administer intravenous somatostatin analogues, fluids, corticosteroids, and electrolytes as indicated.
Embryo-Fetal Toxicity: LUTATHERA can cause fetal harm. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment and for 7 months after the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment and for 4 months after the final dose. Verify pregnancy status of females of reproductive potential prior to initiating LUTATHERA.
Risk of Infertility: LUTATHERA may cause infertility in males and females. Radiation absorbed by testes and ovaries from the recommended cumulative LUTATHERA dose falls within the range in which temporary or permanent infertility can be expected following external beam radiotherapy.

ADVERSE REACTIONS

The most common grade 3 to 4 adverse reactions (≥4% with a higher incidence in the LUTATHERA arm) observed in NETTER-1 were lymphopenia (44%), increased gamma-glutamyl transferase (20%), vomiting (7%), nausea (5%), elevated aspartate aminotransferase (5%), increased alanine aminotransferase (4%), hyperglycemia (4%), and hypokalemia (4%).

In ERASMUS, the following serious adverse reactions have been observed with a median follow-up time of >4 years after treatment with LUTATHERA: myelodysplastic syndrome (2%), acute leukemia (1%), renal failure (2%), hypotension (1%), cardiac failure (2%), myocardial infarction (1%), and neuroendocrine hormonal crisis (1%). Patients should be counseled and monitored in accordance with the LUTATHERA Prescribing Information.

DRUG INTERACTIONS

Somatostatin and its analogues competitively bind to somatostatin receptors and may interfere with the efficacy of LUTATHERA. Discontinue long-acting somatostatin analogues at least 4 weeks and short-acting octreotide at least 24 hours prior to each LUTATHERA dose. Administer short- and long-acting octreotide during LUTATHERA treatment as recommended.

Corticosteroids can induce downregulation of subtype 2 somatostatin receptors. Avoid repeated administration of high doses of glucocorticosteroids during treatment with LUTATHERA.

SPECIFIC POPULATIONS

Lactation: Because of the potential risk for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment with LUTATHERA and for 2.5 months after the final dose.

Please see full Prescribing Information.